Enbrel Indications/Uses

Treatment of active RA in adults when the response to disease-modifying antirheumatic drugs (DMARDs), including methotrexate (unless contraindicated), has been inadequate. Enbrel has been shown to halt disease-associated structural damage when used in combination with methotrexate.
Treatment of severe, active and progressive RA in adults not previously treated with methotrexate.
In patients with RA, Enbrel used alone or in combination with methotrexate has been shown to slow the progression of disease-associated structural damage as measured by x-ray.
Treatment of active polyarticular-course juvenile chronic arthritis in children 4-17 years who have had an inadequate response to, or who have proved intolerant of, methotrexate. Enbrel has not been studied in children <4 years.
Treatment of active and progressive psoriatic arthritis in adults when the response to previous DMARDs therapy has been inadequate.
Treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to previous DMARDs therapy. Treatment of adults with moderate to severe plaque psoriasis who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or PUVA (see Pharmacology under Actions).